Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Becton Dickinson and CoBDX38.303.242.5215.435.63%5.12%36.12$224.10$1,505.7476,744$225.53

Detail of Becton Dickinson and Co

 
CEO
Mr. Thomas E. Polen Jr.
Employees
70000
Industry
Medical Instruments & Supplies
Sector
Healthcare
Market cap
$65B

Company details

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OTH
OI
OIE
PI
TAX
NI
Revenue (Rev)
$20.18B
Cost of goods (CoG)
-$11.05B
Gross profit (GP)
$9.12B
Operating expense (OE)
-$6.27B
Research and development (R&D)
-$1.19B
General and administrative (G&A)
-$4.86B
Other (OTH)
-$222.00M
Operating income (OI)
$2.86B
Other income expense (OIE)
-$486.00M
Pretax income (PI)
$2.01B
Tax (TAX)
-$300.00M
Net income (NI)
$1.70B
Becton Dickinson and Co
BDX • XNYS • US
$225.53
-12.95 (-5.43%)
Stock vs Industry average
  • Industry average

Dividend yield
1.72%
Trailing annual dividend rate
$0.00
Payout ratio
64.85%
EPS
$5.89
Margin profit
7.13%
52 week low
$218.874405
52 week high
$247.729996
50-day simple moving average
$223.48
200-day simple moving average
$224.10
Percent held by insiders
0.28%
Percent held by institutions
91.75%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
BDX -4.82%
eps change
BDX -100.00%